Therapeutic Effects of Electrical Vestibular Stimulation (EVS) on Balance and Gait
Launched by NEURSANTYS INC · Feb 20, 2025
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called Electrical Vestibular Stimulation (EVS) to see if it can help improve balance and walking in people with balance issues. The study will involve healthy individuals of various ages, from 6 to 35 years old, and it aims to find out if using EVS is safe, effective, and if its benefits last over time. Participants will take part in balance and walking tests before, during, and after receiving EVS to measure any changes in their performance.
To join the study, participants should be able to complete balance tests, like standing still with their feet together, and walk a certain distance without help. However, people with certain medical devices like pacemakers, or those with specific health conditions affecting the brain or muscles, cannot participate. The study is currently looking for volunteers, and it's a great opportunity for those who meet the criteria to contribute to research that could lead to better treatments for balance problems in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Able to complete balance assessments such as standing with feet together/eyes open and feet together/eyes closed, both for at least 1 minute at a time, with no more than 1 minute rest required between tests.
- • 2. Able to complete gait assessment tests such as walking up to 200m on a flat surface without assistance.
- Exclusion Criteria:
- • 1. Participants must not be using a pacemaker, cochlear implant, or any other implanted electronic device.
- • 2. Participants must be free from any diagnosed neurological or musculoskeletal injuries and/or disorders other than those explicitly being investigated (i.e., vertigo, multiple sclerosis, Parkinson's disease, concussion).
- • 3. Participants must have the mental capacity to provide consent and perform tasks required by the experiment.
About Neursantys Inc
Neursantys Inc. is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for neurodegenerative diseases. With a strong focus on harnessing cutting-edge scientific research, Neursantys aims to develop novel treatment solutions that address unmet medical needs in conditions such as Alzheimer's disease and other cognitive disorders. The company is committed to rigorous clinical trials and collaborations with leading research institutions, ensuring the highest standards of safety and efficacy in its product development. Through its dedication to improving patient outcomes, Neursantys Inc. is at the forefront of transforming the landscape of neurological care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Cupertino, California, United States
Menlo Park, California, United States
Dieppe, New Brunswick, Canada
Patients applied
Trial Officials
Ryan M Peters, PhD
Principal Investigator
University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported